JPWO2021041208A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021041208A5 JPWO2021041208A5 JP2022512341A JP2022512341A JPWO2021041208A5 JP WO2021041208 A5 JPWO2021041208 A5 JP WO2021041208A5 JP 2022512341 A JP2022512341 A JP 2022512341A JP 2022512341 A JP2022512341 A JP 2022512341A JP WO2021041208 A5 JPWO2021041208 A5 JP WO2021041208A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pyrido
- hexahydro
- isobutyl
- dimethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000009659 Vesicular Monoamine Transport Proteins Human genes 0.000 claims description 54
- 108010020033 Vesicular Monoamine Transport Proteins Proteins 0.000 claims description 54
- 239000003112 inhibitor Substances 0.000 claims description 47
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 32
- 239000012458 free base Substances 0.000 claims description 28
- GEJDGVNQKABXKG-CFKGEZKQSA-N [(2r,3r,11br)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1h-benzo[a]quinolizin-2-yl] (2s)-2-amino-3-methylbutanoate Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](OC(=O)[C@@H](N)C(C)C)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 GEJDGVNQKABXKG-CFKGEZKQSA-N 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 16
- 206010062237 Renal impairment Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 13
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 10
- 208000025966 Neurological disease Diseases 0.000 claims description 10
- 230000000926 neurological effect Effects 0.000 claims description 10
- 208000020016 psychiatric disease Diseases 0.000 claims description 10
- 229940109239 creatinine Drugs 0.000 claims description 8
- 230000003907 kidney function Effects 0.000 claims description 7
- WEQLWGNDNRARGE-DJIMGWMZSA-N (2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol Chemical compound C1CN2C[C@@H](CC(C)C)[C@H](O)C[C@@H]2C2=C1C=C(OC)C(OC)=C2 WEQLWGNDNRARGE-DJIMGWMZSA-N 0.000 claims description 6
- 206010008748 Chorea Diseases 0.000 claims description 6
- 208000012601 choreatic disease Diseases 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims 36
- 238000000034 method Methods 0.000 description 80
- -1 hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl Chemical group 0.000 description 10
- 229950006411 valbenazine Drugs 0.000 description 8
- 208000019022 Mood disease Diseases 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IXKWYZYHMDHNOW-MISYRCLQSA-N CCCC(O[C@H](C1)[C@H](CC(C)C)CN(CCC2=C3)[C@H]1C2=CC(OC)=C3OC)=O Chemical compound CCCC(O[C@H](C1)[C@H](CC(C)C)CN(CCC2=C3)[C@H]1C2=CC(OC)=C3OC)=O IXKWYZYHMDHNOW-MISYRCLQSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- BXGKAGLZHGYAMW-TZYFFPFWSA-N [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate 4-methylbenzenesulfonic acid Chemical compound Cc1ccc(cc1)S(O)(=O)=O.Cc1ccc(cc1)S(O)(=O)=O.COc1cc2CCN3C[C@@H](CC(C)C)[C@@H](C[C@@H]3c2cc1OC)OC(=O)[C@@H](N)C(C)C BXGKAGLZHGYAMW-TZYFFPFWSA-N 0.000 description 2
- MLAYZCMWRNQKQX-UHFFFAOYSA-N 2-hydroxy-1h-isoquinoline Chemical compound C1=CC=C2C=CN(O)CC2=C1 MLAYZCMWRNQKQX-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 208000033895 Choreoacanthocytosis Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 201000008675 chorea-acanthocytosis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000022610 schizoaffective disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000005490 tosylate group Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185429A JP2025003553A (ja) | 2019-08-23 | 2024-10-21 | 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890697P | 2019-08-23 | 2019-08-23 | |
| US62/890,697 | 2019-08-23 | ||
| US202063028754P | 2020-05-22 | 2020-05-22 | |
| US63/028,754 | 2020-05-22 | ||
| PCT/US2020/047392 WO2021041208A1 (en) | 2019-08-23 | 2020-08-21 | Methods for the administration of certain vmat2 inhibitors to patients with severe renal impairment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185429A Division JP2025003553A (ja) | 2019-08-23 | 2024-10-21 | 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022544711A JP2022544711A (ja) | 2022-10-20 |
| JPWO2021041208A5 true JPWO2021041208A5 (https=) | 2023-08-15 |
| JP2022544711A5 JP2022544711A5 (https=) | 2023-08-15 |
| JP7603662B2 JP7603662B2 (ja) | 2024-12-20 |
Family
ID=72292706
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512341A Active JP7603662B2 (ja) | 2019-08-23 | 2020-08-21 | 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 |
| JP2024185429A Pending JP2025003553A (ja) | 2019-08-23 | 2024-10-21 | 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185429A Pending JP2025003553A (ja) | 2019-08-23 | 2024-10-21 | 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10940141B1 (https=) |
| EP (2) | EP4017494B1 (https=) |
| JP (2) | JP7603662B2 (https=) |
| KR (1) | KR20220051239A (https=) |
| CN (1) | CN114679906A (https=) |
| AU (2) | AU2020336017B2 (https=) |
| BR (1) | BR112022002834A2 (https=) |
| CA (1) | CA3149033A1 (https=) |
| DK (1) | DK4017494T3 (https=) |
| ES (1) | ES3040583T3 (https=) |
| FI (1) | FI4017494T3 (https=) |
| HR (1) | HRP20251281T1 (https=) |
| HU (1) | HUE073484T2 (https=) |
| IL (1) | IL290686B2 (https=) |
| JO (1) | JOP20220040A1 (https=) |
| LT (1) | LT4017494T (https=) |
| MA (1) | MA56930B1 (https=) |
| MD (1) | MD4017494T2 (https=) |
| MX (1) | MX2022000559A (https=) |
| PH (1) | PH12022550385A1 (https=) |
| PT (1) | PT4017494T (https=) |
| RS (1) | RS67194B1 (https=) |
| SI (1) | SI4017494T1 (https=) |
| SM (1) | SMT202500480T1 (https=) |
| TW (1) | TWI894161B (https=) |
| WO (1) | WO2021041208A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| ES3024958T3 (en) | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| IL307678A (en) * | 2021-04-15 | 2023-12-01 | Neurocrine Biosciences Inc | Methods of administering certain VMAT2 inhibitors |
| JP2024514873A (ja) * | 2021-04-15 | 2024-04-03 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法 |
| MX2023014977A (es) | 2021-06-30 | 2024-02-09 | Neurocrine Biosciences Inc | Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral. |
| BR112023026691A2 (pt) | 2021-06-30 | 2024-03-05 | Neurocrine Biosciences Inc | Valbenazina para uso no tratamento complementar de esquizofrenia |
| WO2023172849A1 (en) | 2022-03-07 | 2023-09-14 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025038938A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Valbenazine for use in the treatment of huntington's chorea |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5777697A (en) | 1980-11-04 | 1982-05-15 | Nippon Zoki Pharmaceut Co Ltd | Physiologically active substance nsq |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| JPS57209225A (en) | 1981-06-18 | 1982-12-22 | Yamasa Shoyu Co Ltd | Antitumor activity intensifier |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5204329A (en) | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| ZA977967B (en) | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| HUP0000116A3 (en) | 1996-10-01 | 2000-08-28 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| AU1321900A (en) | 1998-10-23 | 2000-05-15 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| AP2001002264A0 (en) | 2000-08-30 | 2001-09-30 | Pfizer Prod Inc | Sustained release formulations for growth hormone secretagogues. |
| WO2003099011A1 (en) | 2002-05-28 | 2003-12-04 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders |
| AU2003272608A1 (en) | 2002-09-19 | 2004-04-08 | University Of Utah Research Foundation | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| TW201422238A (zh) | 2004-06-04 | 2014-06-16 | Genentech Inc | Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品 |
| EP1855677B1 (en) | 2005-08-06 | 2008-12-03 | Cambridge Laboratories (Ireland) Limited | 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses |
| US20100076087A1 (en) | 2005-10-06 | 2010-03-25 | Auspex Pharmaceuticals, Inc. | Methods of reduction of interpatient variability |
| PL2081929T3 (pl) | 2006-11-08 | 2013-06-28 | Neurocrine Biosciences Inc | Podstawione związki 3-izobutylo-9,10-dimetoksy-1,3,4,6,7,11b-heksahydro-2H-pirydo[2,1-a]izochinolin-2-olowe i ich wytwarzania |
| GB0721669D0 (en) | 2007-11-02 | 2007-12-12 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| RU2476431C2 (ru) | 2008-01-18 | 2013-02-27 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Конденсированное производное аминодигидротиазина |
| US20110053866A1 (en) | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| GB2463452A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof |
| GB2463451A (en) | 2008-09-08 | 2010-03-17 | Cambridge Lab | 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia |
| WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US20100096319A1 (en) | 2008-10-17 | 2010-04-22 | General Electric Company | Separator assembly |
| CA2771539A1 (en) | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
| CA2801061A1 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| CN104684555A (zh) | 2012-09-18 | 2015-06-03 | 奥斯拜客斯制药有限公司 | 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学 |
| KR102148990B1 (ko) | 2012-12-18 | 2020-08-27 | 반다 파마슈티칼즈, 인코퍼레이티드. | 일주기 리듬 장애의 치료 |
| EA202091397A1 (ru) | 2013-01-31 | 2020-09-04 | Ауспекс Фармацетикалс, Инк. | Бензохинолоновые ингибиторы vmat2 |
| WO2015077521A1 (en) | 2013-11-22 | 2015-05-28 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EA201691512A1 (ru) | 2014-01-27 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Бензохинолиновые ингибиторы везикулярного переносчика моноамина 2 |
| US10166183B2 (en) | 2014-02-07 | 2019-01-01 | Auspex Pharmaceuticals, Inc. | Pharmaceutical formulations |
| NZ760790A (en) | 2014-02-07 | 2022-11-25 | Neurocrine Biosciences Inc | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
| WO2015171802A1 (en) | 2014-05-06 | 2015-11-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| CA2974540C (en) | 2015-02-06 | 2023-09-26 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| HRP20221106T1 (hr) | 2015-03-06 | 2022-11-25 | Auspex Pharmaceuticals, Inc. | Postupci liječenja abnormalnih nevoljnih poremećaja pokreta |
| EA036837B1 (ru) | 2015-06-23 | 2020-12-25 | Нейрокрин Байосайенсиз, Инк. | Ингибиторы vmat2 для лечения неврологических заболеваний или расстройств |
| MY193767A (en) | 2015-10-30 | 2022-10-27 | Neurocrine Biosciences Inc | Valbenazine salts and polymorphs thereof |
| CN108925135B (zh) | 2015-12-23 | 2025-09-19 | 纽罗克里生物科学有限公司 | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 |
| TW202345829A (zh) | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| WO2018140092A1 (en) | 2017-01-27 | 2018-08-02 | Obrien Christopher F | Methods for the administration of certain vmat2 inhibitors |
| CA3054238A1 (en) * | 2017-02-27 | 2018-08-30 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| CN110678181A (zh) | 2017-04-01 | 2020-01-10 | 阿德普蒂奥制药有限公司 | (+)-α-二氢丁苯那嗪在治疗运动障碍中的用途 |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| US10857144B2 (en) | 2017-05-16 | 2020-12-08 | Bow River LLC | Methods of treatment |
| JP2020520380A (ja) | 2017-05-16 | 2020-07-09 | ボウ リバー エルエルシー | 処置法 |
| ES3024958T3 (en) | 2017-09-21 | 2025-06-05 | Neurocrine Biosciences Inc | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| MX2020013004A (es) | 2018-06-14 | 2021-02-17 | Neurocrine Biosciences Inc | Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos. |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
-
2020
- 2020-08-10 US US16/989,206 patent/US10940141B1/en active Active
- 2020-08-21 TW TW109128566A patent/TWI894161B/zh active
- 2020-08-21 FI FIEP20764910.4T patent/FI4017494T3/fi active
- 2020-08-21 EP EP20764910.4A patent/EP4017494B1/en active Active
- 2020-08-21 IL IL290686A patent/IL290686B2/en unknown
- 2020-08-21 ES ES20764910T patent/ES3040583T3/es active Active
- 2020-08-21 CN CN202080060823.7A patent/CN114679906A/zh active Pending
- 2020-08-21 SM SM20250480T patent/SMT202500480T1/it unknown
- 2020-08-21 PH PH1/2022/550385A patent/PH12022550385A1/en unknown
- 2020-08-21 JP JP2022512341A patent/JP7603662B2/ja active Active
- 2020-08-21 HR HRP20251281TT patent/HRP20251281T1/hr unknown
- 2020-08-21 AU AU2020336017A patent/AU2020336017B2/en active Active
- 2020-08-21 WO PCT/US2020/047392 patent/WO2021041208A1/en not_active Ceased
- 2020-08-21 MD MDE20220730T patent/MD4017494T2/ro unknown
- 2020-08-21 MA MA56930A patent/MA56930B1/fr unknown
- 2020-08-21 BR BR112022002834A patent/BR112022002834A2/pt unknown
- 2020-08-21 LT LTEPPCT/US2020/047392T patent/LT4017494T/lt unknown
- 2020-08-21 RS RS20250893A patent/RS67194B1/sr unknown
- 2020-08-21 PT PT207649104T patent/PT4017494T/pt unknown
- 2020-08-21 HU HUE20764910A patent/HUE073484T2/hu unknown
- 2020-08-21 EP EP25194031.8A patent/EP4652986A3/en active Pending
- 2020-08-21 MX MX2022000559A patent/MX2022000559A/es unknown
- 2020-08-21 KR KR1020227009599A patent/KR20220051239A/ko active Pending
- 2020-08-21 DK DK20764910.4T patent/DK4017494T3/da active
- 2020-08-21 SI SI202030655T patent/SI4017494T1/sl unknown
- 2020-08-21 CA CA3149033A patent/CA3149033A1/en active Pending
-
2022
- 2022-02-20 JO JOP/2022/0040A patent/JOP20220040A1/ar unknown
-
2024
- 2024-10-21 JP JP2024185429A patent/JP2025003553A/ja active Pending
-
2025
- 2025-12-09 AU AU2025279628A patent/AU2025279628A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021041208A5 (https=) | ||
| JP2025116875A5 (https=) | ||
| UA57165C2 (uk) | Кулька з регульованим вивільненням, спосіб її виготовлення, багатоодинична композиція та способи лікування | |
| EP2065038A1 (en) | New therapeutic approaches for treating Charcot-Marie-Tooth disease | |
| JP6974357B2 (ja) | パーキンソン病の治療 | |
| JP2021526138A5 (https=) | ||
| US20140100282A1 (en) | Intranasal administration of pharmaceutical agents for treatment of neurological diseases | |
| CN114901265A (zh) | 用于癌症治疗的btk抑制剂和mdm2抑制剂的组合 | |
| JP2017536380A (ja) | １５−ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| US20030195255A1 (en) | Method for treating hepatic encephalopathies | |
| CN102924456B (zh) | 当以乳清酸盐衍生物给药时降低甲氨蝶呤副作用和毒性的组合物和方法 | |
| JP2021520396A5 (https=) | ||
| CA2465471C (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction | |
| ITRM960396A1 (it) | Uso di alcanoil l-carnitine nel trattamento terapeutico di malattie infiammatorie croniche intestinali. | |
| KR0136559B1 (ko) | 에이즈 및 에이즈 관련 증후군 환자 및 무증후성 hiv 혈청양성 환자 치료를 위한 l-카르니틴 및 아실 l-카르니틴의 용도 | |
| JPH0782146A (ja) | 抗痴呆薬 | |
| WO2020223893A1 (en) | Use of gold nanoclusters in treating hypercholesterolemia or hypercholesterolemia-associated diseases | |
| KR20190127885A (ko) | 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제 | |
| EP3522843B1 (en) | Pramipexole transdermal delivery system and uses thereof | |
| JP2025513240A5 (https=) | ||
| JP7376679B2 (ja) | Ｈｂｖ感染の処置のためのｅｙｐ００１とｉｆｎの相乗効果 | |
| JPWO2019226685A5 (https=) | ||
| JP2008514721A (ja) | 治療方法 | |
| JP6420923B1 (ja) | 医薬 | |
| CN116685316A (zh) | 用于治疗脂质相关失调的组合物和方法 |